Sodium selenite and N‐acetylcysteine in antiretroviral‐naive HIV‐1‐infected patients: a randomized, controlled pilot study
- 1 May 1998
- journal article
- research article
- Published by Wiley in European Journal of Clinical Investigation
- Vol. 28 (5), 389-397
- https://doi.org/10.1046/j.1365-2362.1998.00301.x
Abstract
The aim of this work was to study the effects of combined oral administration of N-acetylcysteine (NAC) and sodium selenite (Se) on plasma glutathione (GSH), lymphocyte subpopulations and viral load in asymptomatic human immunodeficiency virus (HIV)-infected patients. We used a prospective, randomized and controlled therapy trial with partial cross-over. Twenty-four antiretroviral-naive HIV-infected outpatients at Centers for Disease Control (CDC) '93 stages I and II were randomized to receive the antioxidant combination NAC 600 mg t.i.d. and Se 500 μg per day for either 24 weeks (group A, n = 13) or from the end of week 12 (group B, n = 11) until the end of week 24. Thus, group B served as untreated control during the first 12 weeks. There was (a) a trend towards an increase in the percentage of CD4+ lymphocytes after 6 weeks (P = 0.08); (b) an increase in the CD4/CD8 ratio after 6 and 12 weeks (P = 0.02 and P = 0.04 respectively); and (c) a decrease in the absolute CD8/CD38 count and percentage of lymphocytes after 6 weeks (P = 0.002 and P = 0.033 respectively) and 12 weeks (P = 0.033, P = 0.1 respectively) in group A compared with the control period of group B. The effects observed in group A were, however, not paralleled to the same extent by group B after crossing-over to treatment after 12 weeks. In addition, erythrocyte glutathione peroxidase (GSH-Px) activity and GSH, glutathionedisulphide (GSSG) concentrations and the reduced/total GSH ratio were not affected by the treatment. Serum selenium levels increased significantly (P < 0.001) upon treatment. Viral load was not altered. The changes in lymphocyte subsets after NAC/Se treatment were not comparable to those after standard antiretroviral drug therapy. This, however, does not preclude per se possible benefits of antioxidant supplementation in HIV disease.Keywords
This publication has 49 references indexed in Scilit:
- The role of oxidative stress in HIV diseaseFree Radical Biology & Medicine, 1995
- Antioxidant status and lipid peroxidation in patients infected with HIVChemico-Biological Interactions, 1994
- Oxidative stress and apoptosis in HIV infection: a role for plant-derived metabolites with synergistic antioxidant activityImmunology Today, 1994
- Soluble tumour necrosis factor receptors (sTNF-R) and HIV infection: correlation to CD8+ lymphocytesClinical and Experimental Immunology, 1993
- The role of reactive oxygen species, antioxidants and phytopharmaceuticals in human immunodeficiency virus activityMedical Hypotheses, 1993
- Soluble receptors for tumour necrosis factorAIDS, 1993
- Reactive oxygen intermediates and human immunodeficiency virus (HIV) infectionFree Radical Biology & Medicine, 1992
- N-Acetylcysteine: A New Approach to Anti-HIV TherapyAIDS Research and Human Retroviruses, 1992
- Cytokines and HIV infection: is AIDS a tumor necrosis factor disease?AIDS, 1991
- Reactive oxygen species, antioxidants, and acquired immunodeficiency syndrome. Sense or speculation?Archives of Internal Medicine, 1991